Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02303821
Recruitment Status : Recruiting
First Posted : December 1, 2014
Last Update Posted : May 10, 2021
Sponsor:
Collaborators:
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator
Innovative Therapies For Children with Cancer Consortium
Information provided by (Responsible Party):
Amgen

Brief Summary:

The purpose of Phase 1b of this study is to:

  • Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
  • Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy.

The purpose of Phase 2 of this study is to compare the rate of complete response (CR) of carfilzomib in combination with vincristine, dexamethasone, PEG asparaginase, daunorubicin (VXLD) at the end of induction therapy to an appropriate external control.


Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia (ALL) Drug: Carfilzomib Drug: Dexamethasone Drug: Mitoxantrone Drug: PEG-asparaginase Drug: Vincristine Drug: Intrathecal (IT) Methotrexate Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate) Drug: 6-Mercaptopurine Drug: Cyclophosphamide Drug: Cytarabine Drug: Daunorubicin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 118 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Actual Study Start Date : February 16, 2015
Estimated Primary Completion Date : January 22, 2024
Estimated Study Completion Date : January 22, 2024


Arm Intervention/treatment
Experimental: Phase 1b: Dose Escalation 1

Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.

Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.

Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle.

Drug: Carfilzomib
Other Names:
  • PR-171
  • PR171
  • Kyprolis® (carfilzomib) for Injection

Drug: Dexamethasone
Drug: Mitoxantrone
Drug: PEG-asparaginase
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Drug: 6-Mercaptopurine
Drug: Cyclophosphamide
Drug: Cytarabine
Experimental: Phase 1b: Dose Escalation 2

Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.

Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle.

Drug: Carfilzomib
Other Names:
  • PR-171
  • PR171
  • Kyprolis® (carfilzomib) for Injection

Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Drug: 6-Mercaptopurine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Experimental: Phase 2: Aged ≥ 12 months at screening

All subjects aged ≥ 12 months at screening.

Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.

Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle.

Drug: Carfilzomib
Other Names:
  • PR-171
  • PR171
  • Kyprolis® (carfilzomib) for Injection

Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Drug: 6-Mercaptopurine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Experimental: Phase 2: Aged < 12 months at screening

All subjects aged < 12 months at screening.

Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.

Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle.

Drug: Carfilzomib
Other Names:
  • PR-171
  • PR171
  • Kyprolis® (carfilzomib) for Injection

Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Drug: 6-Mercaptopurine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin



Primary Outcome Measures :
  1. Phase 1b: Number of Subjects who Experience One or More Adverse Events (AE) [ Time Frame: 36 months ]
  2. Phase 1b: Number of Subjects who Experience One or More Serious Adverse Events (SAEs) [ Time Frame: 36 months ]
  3. Phase 1b: Number of Subjects who Experienced a Clinically Significant Change from Baseline in Key Laboratory Analytes [ Time Frame: 36 months ]
    Changes from baseline in key laboratory analytes.

  4. Phase 1b: Number of Subjects who Experience a Clinically Significant Change from Baseline in Vital Signs [ Time Frame: 36 months ]
    Changes from baseline in vital signs

  5. Phase 1b: Number of Subjects who Experience a Clinically Significant Change from Baseline in Physical Findings [ Time Frame: 36 months ]
    Changes from baseline in physical findings

  6. Phase 1b: Time to Toxicity [ Time Frame: 36 months ]
    Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy

  7. Phase 1b: Maximum Tolerated Dose (MTD) [ Time Frame: 36 months ]
    Maximum tolerated dose (MTD) of carfilzomib in combination with induction chemotherapy. Determination of the MTD as the dose that has the highest posterior probability of having a dose-limiting toxicity (DLT) rate within the target toxicity interval (20%-33%), while the posterior probability of excessive/unacceptable toxicity (>33%-100%) is less than 40%.

  8. Phase 2: Complete Response (CR) Rate After Induction Therapy in Subjects Aged ≥ 12 Months at Screening [ Time Frame: From Day 29 up to a maximum of Day 45 ]
    CR will be assessed in all subjects who do not show disease progression during induction therapy (Day 1 to Day 28) between Day 29 and Day 45, or start of alternative therapy, whichever comes first. Subjects can receive alternative therapy after completing induction therapy on Day 28.

  9. Phase 2: Complete Response (CR) Rate After Induction Therapy in Subjects Aged < 12 Months at Screening [ Time Frame: From Day 36 up to a maximum of Day 50 ]
    CR will be assessed in all subjects who do not show disease progression during induction therapy (Modified based on Interfant-06: Day 1 to Day 35) between Day 36 and Day 50, or start of alternative therapy, whichever comes first. Subjects can receive alternative therapy after completing induction therapy on Day 35.


Secondary Outcome Measures :
  1. Phase 1b: Maximum plasma concentration (Cmax) [ Time Frame: 36 months ]
    Maximum plasma concentration (Cmax), alone and in combination with induction chemotherapy, will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for Cmax will be tabulated and summarized (i.e., mean, standard deviation).

  2. Phase 1b: Total Plasma Exposure - Area Under the Curve (AUC) [ Time Frame: 36 months ]
    Total Plasma Exposure - Area Under the Curve (AUC), alone and in combination with induction chemotherapy, will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for AUC will be tabulated and summarized (i.e., mean, standard deviation).

  3. Phase 1b: Number of Subjects who Experience Complete Response (CR) or Complete Response with Incomplete Hematological Recovery (CRi) [ Time Frame: 36 months ]
  4. Phase 1b: Minimal Residual Disease (MRD) Status [ Time Frame: 36 months ]
    Proportion of subjects who achieve MRD status < 10-3 and < 10-4 lymphoblasts at the end of the Induction Cycle as assessed by quantitative immunoglobulin/T-cell receptor (Ig/TcR) polymerase chain reaction (PCR)

  5. Phase 2: Number of Subjects who Experience a Treatment-emergent Adverse Event (TEAE) [ Time Frame: 29 months ]
  6. Phase 2: Number of Subjects who Experience a Treatment-related Adverse Event [ Time Frame: 29 months ]
  7. Phase 2: Number of Subjects who Experience a Severe Adverse Event [ Time Frame: 29 months ]
  8. Phase 2: Number of Subjects who Experience a Laboratory Abnormality [ Time Frame: 29 months ]
  9. Phase 2: Number of Subjects who Experience Complete Response (CR), Complete Response with Incomplete Recovery of Platelets (CRp), or Complete Response with Incomplete Hematological Recovery (CRi) [ Time Frame: 29 months ]
  10. Phase 2: Event Free Survival (EFS) [ Time Frame: 29 months ]
    EFS, defined as time from initiation of therapy until treatment failure (defined as failure to reach at least a CRi after consolidation or after induction in subjects that do not receive consolidation), relapse, or death from any cause.

  11. Phase 2: Overall Survival (OS) [ Time Frame: 29 months ]
    OS defined as time from initiation of therapy until death from any cause.

  12. Phase 2: Duration of Response (DOR) [ Time Frame: 29 months ]
    DOR, defined as time from earliest of CR, CRp, CRh, or CRi to relapse or death from any cause.

  13. Phase 2: Minimal Residual Disease (MRD) Status in all Subjects [ Time Frame: 29 months ]
    Proportion of subjects who achieve MRD status < 10-4 lymphoblasts at the end of the Induction Cycle as assessed by quantitative immunoglobulin/T-cell receptor (Ig/TcR) polymerase chain reaction (PCR)

  14. Minimal Residual Disease (MRD) Status in Subjects with Complete Response (CR), CR with Incomplete Recovery of Platelets (CRp), CR with Partial Hematological Recovery (CRh) or CR with Incomplete Hematological Recovery (CRi) [ Time Frame: 29 months ]
    Proportion of subjects who achieve MRD status < 10-3 and < 10-4 lymphoblasts at the end of the Induction Cycle as assessed by quantitative immunoglobulin/T-cell receptor (Ig/TcR) polymerase chain reaction (PCR).

  15. Number of Subjects who Experience a Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR-T) [ Time Frame: 29 months ]
  16. Phase 2: Number of Subjects who Experience a Clinically Significant Change from Baseline in Laboratory Analytes [ Time Frame: 29 months ]
  17. Number of Subjects who Experience Complete Response (CR), CR with Incomplete Recovery of Platelets (CRp), or CR with Incomplete Hematological Recovery (CRi) After Consolidation Therapy in Subjects Aged ≥ 12 Months at Screening [ Time Frame: Day 29 and 45 ]
  18. Number of Subjects who Experience Complete Response (CR), CR with Incomplete Recovery of Platelets (CRp), or CR with Incomplete Hematological Recovery (CRi) After Consolidation Therapy in Subjects Aged ≥ 12 Months at Screening [ Time Frame: Day 36 to 50 ]
  19. Phase 2: Maximum Plasma Concentration (Cmax) [ Time Frame: 29 months ]
  20. Phase 2: Area Under the Concentration-time Curve (AUC) [ Time Frame: 29 months ]
  21. Phase 2: Half-life (t1/2) of Carfilzomib [ Time Frame: 29 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Phase 1b Key Inclusion Criteria:

  1. Age 21 years or younger at the time of initial ALL diagnosis and age > 1 year at the time of study treatment initiation.
  2. Subjects must have a diagnosis of relapsed or refractory ALL with ≥ 5% blasts in the bone marrow (M2 or M3 disease), with or without extramedullary disease.

    -To be eligible, subjects must have had 1 or more prior therapeutic attempts, defined as:

    • Early first relapse (< 36 months from original diagnosis) after achieving a CR (B-ALL) or first relapse any time following the original diagnosis after achieving a CR (T-ALL)
    • First refractory bone marrow relapse occurring any time after original diagnosis after achieving a CR (ie, ≥1 failed attempt to induce a second remission) OR
    • Relapse after achieving a CR following the first or subsequent relapse (i.e., ≥ 2 relapses) OR
    • Failing to achieve a CR from original diagnosis after at least 1 induction attempt
  3. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.
  4. Subjects must have a serum creatinine level that is ≤ 1.5 × institutional upper limit of normal (ULN) according to age. If serum creatinine level is > 1.5 × ULN, the subject must have a calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m2.
  5. Adequate liver function, defined as both of the following:

    • Total bilirubin ≤ 1.5 × institutional ULN except in the presence of Gilbert Syndrome
    • Alanine aminotransferase (ALT) ≤ 5 × institutional ULN
  6. Performance status: Karnofsky or Lansky scores ≥ 50 for subjects > 16 years old or ≤ 16 years old, respectively.

Phase 2 Inclusion Criteria:

  1. Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
  2. Age ≥ 1 month to < 21 years. Subjects ≥ 18 years must have had their original diagnosis at < 18 years of age.
  3. Subjects must be diagnosed with relapsed or refractory relapsed ALL.
  4. Subjects must have a documented first remission, ≤ 5% blasts in the bone marrow (M1 bone marrow) and no evidence of extramedullary disease.
  5. T-cell ALL with bone marrow relapse (defined as ≥ 5% leukemia blasts in bone marrow) or refractory relapse with or without extramedullary disease.

    OR B-cell ALL bone marrow relapse or refractory relapse (defined as ≥ 5% leukemia blasts in bone marrow) after having received a targeted B-cell immune therapy as treatment for a prior relapse (eg, blinatumomab, inotuzumab or a CAR-T therapy) with or without extramedullary disease. Subjects that received blinatumomab for treatment of MRD positive disease during first remission or for primary induction failure to achieve a first remission do not qualify.

  6. Adequate liver function: bilirubin ≤ 1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 5 x ULN.
  7. Adequate renal function: serum creatinine ≤ 1.5 x ULN or glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m^2; or for children < 2 years of age ≥ 50 mL/min/1.73 m^2.
  8. Adequate cardiac function: shortening fraction ≥ 30% or ejection fraction ≥ 50%.
  9. Karnofsky (subjects ≥ 16 years of age) or Lansky (subjects 12 months to < 16 years of age) performance status ≥ 50%.
  10. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment (for example: recovery from gastrointestinal toxicity may occur more rapidly than less reversible organ toxicities such as sinusoidal obstruction syndrome or non-infectious pneumonitis, for serious prior toxicities recommended discussion with Amgen medical monitor).
  11. Life expectancy of > 6 weeks per investigator's judgement at time of screening.

Phase 1b Key Exclusion Criteria:

  1. Known allergy to any of the drugs used in the study (Subjects who have had a previous allergy to PEG-asparaginase and if able, may receive Erwinia asparaginase at the investigator's discretion)
  2. Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
  3. Left ventricular fractional shortening < 30%
  4. History of ≥ Grade 2 pancreatitis
  5. Active graft-versus-host disease requiring systemic treatment
  6. Positive culture for or other clinical evidence of infection with bacteria or fungus within 14 days of the initiation of study treatment
  7. Down Syndrome
  8. Prior therapy restrictions:

    • Subjects must have completed therapy with granulocyte-colony stimulating factor (G-CSF) or other myeloid growth factors at least 7 days before study treatment initiation, or at least 14 days before study treatment initiation, if pegylated myeloid growth factors were administered.
    • Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
    • Subjects must have received the last dose of a non-monoclonal antibody biologic agent at least 7 days before study treatment initiation.
    • At least 3 antibody half-lives must have elapsed since the last dose of monoclonal antibody (e.g., 66 days for rituximab and 69 days for epratuzumab) before subjects may initiate study treatment.
    • Subjects must not have received other antineoplastic agents with therapeutic intent, excluding hydroxyurea and antimetabolites administered as part of maintenance chemotherapy, within 7 days prior to study treatment initiation.
  9. Hepatitis B infection with positive hepatitis B DNA

Phase 2 Exclusion Criteria:

  1. Prior treatment with carfilzomib.
  2. Prior treatment with a proteasome inhibitor (other than carfilzomib) within < 3 months of enrollment or to which a subject did not respond (response is defined as bone marrow with < 5% blasts).
  3. Treatment with a chemotherapy regimen including a vinca alkaloid, steroid, L-asparaginase, and anthracycline combination with or without other chemotherapy agents within 2 months of enrollment (eg VXLD, VPLD, R3).
  4. Intolerance, hypersensitivity, or inability to receive any of the chemotherapy components of the VXLD regimen. An exception is allowed for allergy to asparaginase products if Erwinia asparaginase is unable to be administered,
  5. Autologous HSCT within 6 weeks prior to start of study treatment.
  6. Allogeneic HSCT within 3 months prior to start of study treatment.
  7. Active GVHD requiring systemic immune suppression.
  8. < 30 days from discontinuation of immune suppressive therapy administered for the treatment of acute or chronic GVHD.
  9. Isolated extramedullary relapse.
  10. Positive bacterial or fungal infection within 14 days of enrollment (except for documented line infection, line has been removed, and blood culture after line removal is negative for 5 days prior to first dose of induction therapy). Antibiotics may be administered for prophylaxis as per institutional standards up to and after enrollment.
  11. < 3 antibody half-lives since the last dose of monoclonal antibody (eg, 66 days for rituximab, 69 days for epratuzumab, inotuzumab for 36 days), prior to first dose of investigational product.
  12. Cell-based immunotherapy (eg, donor leucocyte infusion, CAR-T cells, tumor vaccines) within 42 days prior to first dose of investigational product. If the Amgen medical monitor agrees, an exception may be granted to the 42-day requirement for subjects with rapidly rising peripheral or bone marrow blast counts.
  13. Down's syndrome.
  14. Presence of another active cancer.
  15. History of grade ≥ 2 pancreatitis within 6 months to screening.
  16. Unresolved toxicities from prior anticancer therapy, defined as not having resolved to CTCAE version 4.03 grade 1 or to levels dictated in the eligibility criteria apart from alopecia or toxicities from prior anticancer therapy that are considered irreversible and do not trigger another exclusion criterion (defined as having been present and stable for > 4 weeks).
  17. Antitumor therapy (chemotherapy, investigational agents, molecular-targeted therapy) within 7 days of day 1 of induction. Exception: hydroxyurea to control peripheral blood leukemic cell counts is allowed until start of investigational product.
  18. Active viral infection, including but not limited to CMV, Hepatitis B infection with positive serum hepatitis surface antigen or hepatitis B DNA, HIV, Hepatitis C with detectable hepatitis C RNA. Subjects who have previously received a stem cell transplant must be screened for CMV infection.
  19. Currently receiving treatment in another investigational device or product study, or < 14 days since ending treatment on another investigational device or product study.
  20. Uncontrolled arrhythmias or screening ECG with corrected QT interval (QTc) of > 470 msec.
  21. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  22. Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 months after the last dose of any study treatment or for 12 months after last dose of cyclophosphamide if administered during optional consolidation cycle.
  23. Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 6 months after the last dose of any study treatment or for 12 months after last dose of cyclophosphamide if administered during optional consolidation cycle.
  24. Female subjects of childbearing potential with a positive pregnancy test assessed at Screening by a serum or urine pregnancy test.
  25. Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use a condom with spermicide during treatment and for an additional 6 months after the last dose of any study treatment, even if they have undergone a successful vasectomy.
  26. Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom with spermicide during treatment, for duration of pregnancy, and for an additional 6 months after the last dose of any study treatment.
  27. Male subjects unwilling to abstain from donating semen or sperm during treatment and for an additional 6 months after the last dose of any study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02303821


Contacts
Layout table for location contacts
Contact: Amgen Call Center 866-572-6436 medinfo@amgen.com

Locations
Layout table for location information
United States, California
Research Site Completed
Los Angeles, California, United States, 90027
United States, Colorado
Research Site Recruiting
Aurora, Colorado, United States, 80045
United States, District of Columbia
Research Site Completed
Washington, District of Columbia, United States, 20010
United States, Florida
Research Site Completed
Miami, Florida, United States, 33136
Research Site Completed
Saint Petersburg, Florida, United States, 33701
United States, Georgia
Research Site Recruiting
Atlanta, Georgia, United States, 30342
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States, 60611
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States, 21231
United States, Michigan
Research Site Completed
Ann Arbor, Michigan, United States, 48109-5718
United States, Minnesota
Research Site Completed
Minneapolis, Minnesota, United States, 55404
United States, New York
Research Site Recruiting
New York, New York, United States, 10032
United States, North Carolina
Research Site Recruiting
Charlotte, North Carolina, United States, 28203
United States, Ohio
Research Site Recruiting
Cincinnati, Ohio, United States, 45229
Research Site Recruiting
Columbus, Ohio, United States, 43205
United States, Tennessee
Research Site Recruiting
Memphis, Tennessee, United States, 38105
United States, Texas
Research Site Recruiting
Dallas, Texas, United States, 75235
Research Site Recruiting
Houston, Texas, United States, 77030
United States, Utah
Research Site Recruiting
Salt Lake City, Utah, United States, 84113
United States, Wisconsin
Research Site Recruiting
Milwaukee, Wisconsin, United States, 53226
Australia, New South Wales
Research Site Recruiting
Randwick, New South Wales, Australia, 2031
Australia, Queensland
Research Site Recruiting
South Brisbane, Queensland, Australia, 4101
Australia, Victoria
Research Site Recruiting
Parkville, Victoria, Australia, 3052
Austria
Research Site Recruiting
Wien, Austria, 1090
Canada, Ontario
Research Site Completed
Toronto, Ontario, Canada, M5G 1X8
Canada, Quebec
Research Site Recruiting
Montreal, Quebec, Canada, H3T 1C5
Denmark
Research Site Recruiting
Kobenhavn O, Denmark, 2100
France
Research Site Recruiting
Bordeaux Cedex, France, 33076
Research Site Recruiting
Lille, France, 59037
Research Site Recruiting
Paris, France, 75012
Research Site Recruiting
Paris, France, 75019
Research Site Recruiting
Toulouse Cedex 9, France, 31059
Research Site Recruiting
Vandoeuvre les Nancy, France, 54511
Israel
Research Site Recruiting
Tel Hashomer, Israel, 5262000
Italy
Research Site Recruiting
Monza (MB), Italy, 20900
Research Site Recruiting
Roma, Italy, 00165
Netherlands
Research Site Completed
Rotterdam, Netherlands, 3015 CN
Spain
Research Site Recruiting
Madrid, Spain, 28009
Switzerland
Research Site Completed
Zuerich, Switzerland, 8032
United Kingdom
Research Site Completed
Birmingham, United Kingdom, B4 6NH
Research Site Completed
London, United Kingdom, WC1N 3JH
Research Site Completed
Manchester, United Kingdom, M13 9WL
Research Site Completed
Newcastle upon Tyne, United Kingdom, NE1 4LP
Research Site Recruiting
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Amgen
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator
Innovative Therapies For Children with Cancer Consortium
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02303821    
Other Study ID Numbers: CFZ008
2014-001633-84 ( EudraCT Number )
First Posted: December 1, 2014    Key Record Dates
Last Update Posted: May 10, 2021
Last Verified: February 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cytarabine
Dexamethasone
Hydrocortisone
Cyclophosphamide
Methotrexate
Vincristine
Daunorubicin
Asparaginase
Mercaptopurine
Mitoxantrone
Pegaspargase
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Inflammatory Agents